The Marketing of the First Cannabis Oil Produced in Argentina Was Authorized

The National Administration of Medicines, Food and Medical Technology (Anmat) authorized a few days ago the distribution and commercialization of the first medical cannabis oil produced by the state-owned company Cannava, from the province of Jujuy.

The agency granted the company the “Sanitary Authorization of the Cannabis-based plant product and its derivatives for use and application in human medicine”. The company estimates that before the end of the year, the product will be available in pharmacies all over the country.

It was informed that any patient with a medical prescription for any pathology will be able to buy the oil and it is not necessary to be authorized by the National Ministry of Health through the Reprochan, which is the registry that enables medicinal users to have, cultivate and transport cannabis flowers or plants.

Read more about the first medical cannabis oil produced in Argentina and approved for marketing, and find other important cannabis news of the day with the Born2Invest mobile app.

Any patient with a medical prescription will be able to buy the cannabis oil

“Cannabis has accompanied mankind since its beginnings and its prohibition is less than a century old, although that is a long time for us”, says Silvia Kochen, a scientist of the Network of Cannabis for Medicinal and Industrial Use CONICET.

And she assured: “that knowledge was kept in the community and that is what is happening now, it is appearing in all its power, there are multiple types of research that are being done in different pathologies, a diversity of scientific posters were presented showing all the work in research and creating a state of legitimacy, where most of the population leaves aside the adverse, distrustful look, due to the prejudice in the use of cannabis and its prohibition has already started to be diluted. I believe that the future is being written here.”

For whom is the cannabis oil intended

This product is intended for people with conditions such as refractory epilepsy, advanced tumors, and chronic pain, which “is also a way out of medical hegemony and to think of a very safe product that generates wellbeing for people,” said Carla Vizzotti, Minister of Health of the Nation.

“Sometimes, even if it does not cure, alleviating is also a challenge and implies seeing the person as a subject of rights,” added the minister.

CBD 10 is consumed orally and has already been given to patients from Jujuy with different ailments who remain hospitalized in the public hospital of the city of Perico.

The official affirmed that the initiatives are successful thanks to the fact that “public research with innovation, development” gives rise to “import substitution and the possibility of exporting, always with a view to public-private articulation and the State playing the leading role in order to achieve it.”

Vizzotti said that the national government is working to obtain “international approvals” and thus expand the new medicinal product, which he assured is of high quality.

__

(Featured image by The Bio Brand via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in EL LITORAL105. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.